Pregnancy shows a positive impact on HIV disease progression

HIV Treatment Bulletin - Vol. 8, No. 10, October 2007

Studies conducted in HIV-positive women receiving either no ART or AZT prophylaxis (HAART) showed that pregnancy either slightly increased the risk of HIV disease progression or had no effect.

A paper authored by Tai and coworkers from Vandebilt University School of Medicine and Comprehensive Care Centre, Nashville, Tennessee, reported findings from an observational cohort study to evaluate disease progression in pregnant women receiving care between 1 January 1997 and 31 December 2004.

In this study HIV disease progression was defined as an AIDS defining illness or death. The investigators found that 759 women met the inclusion criteria; 139 (18%) had at least one pregnancy during follow-up.

There were 174 pregnancies during the study period; 30 women had two pregnancies and five women had three pregnancies. Altogether there were 124 live births, nine spontaneous abortions, three elective abortions, two stillbirths, and one ectopic pregnancy.

In this analysis pregnant women were younger (25, IQR 23-31 years vs. 36, IQR 30-42 years), had higher median baseline CD4 counts (450, IQR 312-660 cells/mm³ vs. 352, IQR 177-560 cells/mm³) and had lower median baseline viral load (3.9, IQR 3.1-4.6 log₁₀ copies/mL vs. 4.2, IQR 3.2-4.9 log₁₀ copies/mL).

119 pregnant and 421 nonpregnant women received HAART and 20 pregnant and 55 nonpregnant women received non- HAART ART only (defined as dual or mono therapy). All pregnant women received ART. Pregnant women were more likely than nonpregnant women to receive HAART. Treatment duration was comparable for pregnant and nonpregnant women.

Pregnant women were more likely to achieve durable virologic suppression (defined as <400 copies/mL) and longer duration of follow-up.

Pregnant women were less likely to have intravenous drug use as a risk factor for HIV acquisition.

The investigators found 11(8%) pregnant and 149 (24%) nonpregnant women either progressed to AIDS or died. The AIDS defining illnesses in pregnant women were Candida oesophagitis, cytomegalovirus retinitis, disseminated cryptococcosis, lymphoma, wasting syndrome, Pneumocystis jirovecii pneumonia and recurrent bacterial pneumonia. In multivariate analysis, after adjusting for baseline CD4 count, and viral load, age, and durable virologic suppression, pregnancy was associated with a decreased risk of disease progression (HR, 0.40 [95%CI, 0.21–0.76); p=0.005).

In a multivariate analysis that included the propensity score for pregnancy in addition to other significant predictors, the risk of disease progression was again significantly lower in pregnant women than in nonpregnant women (HR, 0.40 [95% CI, 0.20–0.79]; p=0.009).

The investigators performed an analysis of 81 matched pregnant and nonpregnant pairs according to age, baseline CD4 count, receipt of HAART, and date of cohort entry. Pregnant women had a lower risk of disease progression both before (HR, 0.10 [95% CI, 0.01-0.89], p=0.04), and after (HR, 0.44 [95%CI, 0.19-1.00], p=0.05) pregnancy.

The investigators wrote: “Our data suggest that, in a setting with high rates of HAART use, pregnancy is independently associated with a decreased risk of HIV disease progression. Further investigation into the responsible underlying biological mechanisms is warranted, particularly the interaction between ART and the immunological changes that occur during pregnancy.”

In an accompanying editorial commentary Kathryn Anastos added: “…women can now have greater confidence that, in addition to protecting their children from MTCT with HAART, their own health will not be compromised by pregnancy, which would place their children at long term risk. For all women pregnancy is something of a gamble: there is no guarantee of a normal pregnancy or a healthy baby. For HIV-infected women becoming pregnant, the findings of Tai et al suggest that, at least for disease progression, the odds may be in their favour.”

2007-10-10
IB070810-14

©2007. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.